Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.32 |
| ▸ | MARS1 | P56192 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672317 | 0.89 | MGLL (0.39) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6671678 | 0.86 | MGLL (0.37) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6672829 | 0.85 | DPP4 (0.36) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6670748 | 0.84 | MGLL (0.38) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6694684 | 0.84 | MGLL (0.38) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6670063 | 0.82 | MGLL (0.40) | MGLLDPP4ALDH1A1LMNAHPGD | |
| SCHEMBL6670911 | 0.79 | MARS1 (0.38) | MGLLALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL6670565 | 0.79 | SLC6A2 (0.33) | ALDH1A1HPGDMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL6671257 | 0.79 | SLC6A2 (0.33) | ALDH1A1HPGDMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL6669412 | 0.77 | MGLL (0.43) | MGLLDPP4ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | disclosed |
| EP-1404679-A2 | (HETERO)ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2003004501-A2 | (HETERO) ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | MGLL 3067/4885DPP4 2209/4885ALDH1A1 456/4885 |
| US-20030050304-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | MGLL 3067/4885DPP4 2209/4885ALDH1A1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.